A phase II/III, randomized, placebo-controlled study of bintrafusp alfa with gemcitabine plus cisplatin as first-line treatment of biliary tract cancer

被引：3

作者：

Oh, D-Y. ^{[1
]}

de Braud, F. ^{[2
]}

Bridgewater, J. ^{[3
]}

Furuse, J. ^{[4
]}

Hsu, C-H. ^{[5
]}

Ikeda, M. ^{[6
]}

Javle, M. ^{[7
]}

Moehler, M. ^{[8
]}

Park, J. O. ^{[9
]}

Shen, L. ^{[10
]}

Yoo, C. ^{[11
]}

Helwig, C. ^{[12
]}

Osada, M. ^{[13
]}

Borad, M. ^{[14
]}

机构：

[1] Seoul Natl Univ, Seoul Natl Univ Hosp, Canc Res Inst, Coll Med, Seoul, South Korea

[2] Univ Milan, Fdn IRCCS Ist Nazl Tumori, Milan, Italy

[3] UCL, Res Dept Oncol, Inst Canc, London, England

[4] Kyorin Univ, Dept Med Oncol, Sch Med, Tokyo, Tokyo, Japan

[5] Natl Taiwan Univ Hosp, Dept Med Oncol, Taipei, Taiwan

[6] Natl Canc Ctr Hosp East, Hepatobiliary & Pancreat Oncol Dept, Kashiwa, Chiba, Japan

[7] Univ Texas MD Anderson Canc Ctr, Gastrointestinal Med Oncol, Houston, TX 77030 USA

[8] Mainz Univ Hosp, Dept Gastroenterol, Hepatol, Mainz, Germany

[9] Sungkyunkwan Univ, Samsung Med Ctr, Sch Med, Seoul, South Korea

[10] Peking Univ, Key Lab Carcinogenesis & Translat Res, Dept Gastrointestinal Oncol, Minist Educ Beijing,Canc Hosp & Inst, Beijing, Peoples R China

[11] Univ Ulsan, Med Ctr, Coll Med, Seoul, South Korea

[12] Merck KGaA, Biostat, Darmstadt, Germany

[13] Merck Biopharma, Biostat, Tokyo, Japan

[14] Mayo Clin, Ctr Canc, Oncol, Scottsdale, AZ USA

来源：

关键词：

D O I：

10.1016/j.annonc.2020.08.057

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

79TiP

引用

页码：S271 / S272

页数：2